Third Harmonic Bio IncNASDAQ:THRD
- LAST PRICE13.8650
- TODAY'S CHANGE (%)-0.3650 (-2.5650%)
- Bid / Lots8.4000/ 2
- Ask / Lots14.0600/ 1
- Open / Previous Close14.5800 / 14.2300
- Day Range
- 52 Week Range
- Volume62,843
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | THRD |
|---|---|---|
| 09:32 ET | 3807 | 14.58 |
| 09:34 ET | 1289 | 14.45 |
| 09:36 ET | 247 | 14.41 |
| 09:48 ET | 100 | 14.51 |
| 09:56 ET | 739 | 14.405 |
| 10:03 ET | 400 | 14.375 |
| 10:28 ET | 100 | 14.31 |
| 10:33 ET | 100 | 14.37 |
| 10:35 ET | 174 | 14.368 |
| 10:39 ET | 800 | 14.26 |
| 10:42 ET | 400 | 14.31 |
| 10:50 ET | 100 | 14.19 |
| 10:51 ET | 100 | 14.19 |
| 10:55 ET | 100 | 14.23 |
| 11:04 ET | 100 | 14.16 |
| 11:08 ET | 900 | 14.09 |
| 11:09 ET | 1085 | 14.13 |
| 11:11 ET | 300 | 14.06 |
| 11:22 ET | 100 | 14.06 |
| 11:29 ET | 100 | 14.06 |
| 11:44 ET | 100 | 14.05 |
| 12:00 ET | 200 | 14.01 |
| 12:05 ET | 100 | 14.01 |
| 12:07 ET | 100 | 13.99 |
| 12:14 ET | 200 | 13.995 |
| 12:21 ET | 100 | 13.96 |
| 12:23 ET | 100 | 13.9624 |
| 12:30 ET | 100 | 13.995 |
| 12:32 ET | 100 | 13.96 |
| 12:34 ET | 150 | 14.029 |
| 12:38 ET | 100 | 13.97 |
| 12:39 ET | 100 | 13.96 |
| 12:41 ET | 600 | 14.05 |
| 12:43 ET | 100 | 14.02 |
| 12:48 ET | 400 | 14.035 |
| 12:57 ET | 300 | 14.045 |
| 01:14 ET | 100 | 13.99 |
| 01:46 ET | 1200 | 13.99 |
| 02:02 ET | 100 | 13.93 |
| 02:08 ET | 300 | 13.89 |
| 02:09 ET | 450 | 13.92 |
| 02:26 ET | 100 | 13.86 |
| 02:27 ET | 100 | 13.85 |
| 02:31 ET | 100 | 13.81 |
| 02:33 ET | 100 | 13.784 |
| 02:38 ET | 600 | 13.7201 |
| 02:42 ET | 100 | 13.74 |
| 02:44 ET | 100 | 13.75 |
| 02:47 ET | 281 | 13.73 |
| 02:49 ET | 300 | 13.75 |
| 02:54 ET | 126 | 13.7894 |
| 02:56 ET | 100 | 13.75 |
| 02:58 ET | 354 | 13.81 |
| 03:02 ET | 100 | 13.76 |
| 03:05 ET | 622 | 13.85 |
| 03:09 ET | 598 | 13.85 |
| 03:12 ET | 100 | 13.84 |
| 03:14 ET | 100 | 13.78 |
| 03:16 ET | 433 | 13.77 |
| 03:18 ET | 593 | 13.83 |
| 03:20 ET | 100 | 13.83 |
| 03:27 ET | 585 | 13.91 |
| 03:34 ET | 2347 | 13.925 |
| 03:36 ET | 300 | 13.93 |
| 03:39 ET | 500 | 13.89 |
| 03:43 ET | 200 | 13.84 |
| 03:45 ET | 300 | 13.86 |
| 03:48 ET | 200 | 13.84 |
| 03:50 ET | 100 | 13.8255 |
| 03:52 ET | 936 | 13.77 |
| 03:56 ET | 500 | 13.78 |
| 03:57 ET | 4922 | 13.835 |
| 03:59 ET | 968 | 13.865 |
May 15, 2024
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update, from 8:05AM ET on Wednesday May 15, 2024 by Dow Jones
8:05AM ET on Wednesday May 15, 2024 by Dow JonesPress Release: Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update, from 8:05AM ET on Wednesday May 15, 2024 by Dow Jones
8:05AM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Third Harmonic Bio Inc | 564.5M | -14.7x | --- |
Mereo BioPharma Group PLC | 448.9M | -12.1x | --- |
Altimmune Inc | 567.9M | -5.0x | --- |
enGene Holdings Inc | 572.4M | -2.8x | --- |
Allogene Therapeutics Inc | 577.2M | -1.6x | --- |
Olema Pharmaceuticals Inc | 550.4M | -4.9x | --- |
Company Information
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
Contact Information
- Headquarters
- 1700 Montgomery Street, Suite 210SAN FRANCISCO, CA, United States 94111
- Phone
- 209-727-2457
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Iwicki
- Chief Executive Officer, Director
- Natalie Holles
- Chief Financial and Business Officer and Principal financial officer
- Christopher Murphy
- Chief Administrative Officer
- Julie Person
- Chief Medical Officer
- Edward Conner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $564.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 40.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.95 |
Book Value | $6.71 |
P/E Ratio | -14.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
